equityflowunderstand the flow and follow it

EquityFlow › Companies › Genesis Therapeutics

Genesis Therapeutics

Biotech · Burlingame, US

AI-driven small-molecule drug discovery platform (GEMS)

Founders

Evan Feinberg (United States · ♂) — After a Yale physics degree and a Stanford PhD in computational biophysics where he built the PotentialNet ML framework for drug discovery, he founded Genesis Therapeutics to apply AI to small-molecule drug discovery.

Team & hubs

In the network

Shares the most investors with (number = shared investors):

Circle Internet Financial 2 Databricks 2 PsiQuantum 2 Rapyd 2 Revolut 2 Waabi 2 xAI 2

Funding history

Date	Round	Amount
Aug 2023	Funding round US AI drug-discovery company Genesis Therapeutics raised a $200m round co-led by Andreessen Horowitz, with Fidelity, BlackRock and NVentures.	$200M

Investors

Tap an investor to see what else they have backed.

Andreessen Horowitz BlackRock Fidelity Management and Research NVentures

Other companies in Biotech

Imperagen Haga Bioscience Pixelgen Technologies Gallant Chai Discovery SNIPR Biome Cellbox Labs Scope Biosciences GenLumina Actithera NUCLIDIUM Anocca

Other companies in US

Supabase Groq Corgi Triomics Stord Patina Status AI Stilta Nectar Social Synthetic Kalshi Musely

Other companies at Unknown stage

&Charge /dev/agents 123-Transporter 123fahrschule 13Hz 1Global 1Komma5°1MT Nation 1Password 20Face 21.co 2NA FISH

Explore funding flow on EquityFlow →

Data is community-curated and may be incomplete.